Premium
In vivo anti‐inflammatory efficacy of the combined Bowman‐Birk trypsin inhibitor and genistein isoflavone, two biological compounds from soybean
Author(s) -
Sadeghalvad Mona,
MohammadiMotlagh HamidReza,
Karaji Ali Gorgin,
Mostafaie Ali
Publication year - 2019
Publication title -
journal of biochemical and molecular toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.526
H-Index - 58
eISSN - 1099-0461
pISSN - 1095-6670
DOI - 10.1002/jbt.22406
Subject(s) - genistein , pharmacology , tumor necrosis factor alpha , in vivo , lipopolysaccharide , chemistry , inflammation , antioxidant , conjugate , biochemistry , biology , endocrinology , immunology , microbiology and biotechnology , mathematical analysis , mathematics
Abstract Soybean Bowman‐Birk protease inhibitor (BBI) and genistein, two biological compounds from soybean, are well‐known for their anti‐inflammatory, antioxidant, and anticancer activities. The aim of this study was designing a BBI‐genistein conjugate and then investigating its protective effect on lipopolysaccharide (LPS)‐induced inflammation in BALB/c mice, compared with the effects of combination of BBI and genistein. BBI was purified from soybean and the BBI‐genistein conjugate was synthesized. The BALB/c mice were intraperitoneally treated 2 hours before LPS induction. Our results showed that treatment with the combination of BBI and genistein greatly led to more reduced serum levels of tumor necrosis factor (TNF)‐α and interferon (IFN)‐γ compared with the treatments of BBI alone, the BBI‐genistein conjugate, and genistein alone, respectively. Moreover, the expression of TNF‐α and IFN‐γ in the splenocytes was significantly downregulated along with improving host survival against the LPS‐induced lethal endotoxemia in the same way. Our data support a new combined therapy using BBI and genistein, as natural anti‐inflammatory agents, to develop a new drug for inflammatory diseases.